Stimulation of cell surface plasminogen activation by heparin and related polyionic substances.
The functional operation of the cell surface pro-u-PA and plasminogen activating system has previously been shown to depend on the assembly of u-PA receptors, plasminogen binding sites, and their respective ligands at the focal adhesions of cell extensions. We now show that additional factors operate that affect the persistence of functional activity and that evidently involve charge interactions mediated by polyanions, such as those found in the cell surface proteoglycans. Heparin-like compounds and protamine were identified as fast-acting stimulators of cell surface plasminogen activation. Heparin stabilized surface u-PA activity during plasminogen activation, and we propose that a heparin binding site exists in the kringle structure of u-PA. Heparin at 40 micrograms/ml could reduce u-PA loss to only 20% compared with 60% on control cells activating plasminogen. Protamine (25 micrograms/ml) exerted a strong stimulatory effect on the level of generated bound plasmin and notably prolonged the persistence of this activity, so that 100 minutes after addition of plasminogen the level of plasmin on protamine-treated cells was five times higher than on control-treated cells. The effect of protamine on plasmin clearance suggests that an unknown plasmin inhibitor may be produced by rhabdomyosarcoma cells, whose action is accelerated by endogenous polyanions, in an analogous manner to thrombin inactivation by antithrombin III and protease nexin on endothelial cells and fibroblasts, respectively. The stimulatory effects of heparin and protamine do not affect the inactivation of cell surface u-PA by recombinant PAI-2.
Stephens
R W
RW
Department of Virology, University of Helsinki, Finland.
Pöllänen
J
J
Tapiovaara
H
H
Woodrow
G
G
Vaheri
A
A
D005341:Fibrinolysin / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D008565:Membrane Proteins / Q000187:drug effects* / Q000378:metabolism; D011479:Protamines / Q000494:pharmacology*; D011485:Protein Binding; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000187:drug effects* / Q000378:metabolism
D008565:Membrane Proteins; D011479:Protamines; D006493:Heparin; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator